文献速递传染病防控与疫情报告慢病防控与筛查

比利时2013至2023年耐莫匹罗星变异株在欧洲流行性耐夫西地酸脓疱疮克隆中的出现与传播

Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium, 2013 to 2023.
PubMed 文献 · Euro Surveill · 2024-01-01

该研究分析了2013至2023年比利时两所大型实验室社区获得性皮肤软组织感染相关的甲氧西林敏感金黄色葡萄球菌(MSSA)对夫西地酸和莫匹罗星的耐药情况。莫匹罗星耐药率从0.5-1.5%上升至1.7-5.6%,2018至2023年间91.4%(64/70)的莫匹罗星耐药分离株同时对夫西地酸耐药。测序的33株中29株为序列型121,携带mupA、fusB及eta、etb基因,与2020年比利时观察到的欧洲流行性耐夫西地酸脓疱疮克隆(EEFIC)亲缘较远,作者认为该耐莫匹罗星EEFIC变异株在儿童中传播值得关注。

要点

  • 莫匹罗星耐药率从2013年的0.5-1.5%上升至2023年的1.7-5.6%。
  • 2018至2023年91.4%(64/70)莫匹罗星耐药株同时对夫西地酸耐药。
  • 截至2023年9月,两实验室儿童分离株共耐药率为8.9%(15/168)至10.1%(11/109)。

核心结论

  • 作者强调一种耐莫匹罗星的EEFIC在儿童中传播,并呈第三季度季节性趋势,该变异株对ikel两种主要外用抗生素均耐药,值得关注。

研究设计与样本

  • 收集2013至2023年比利时两所大型实验室皮肤软组织感染相关MSSA对夫西地酸和莫匹罗星耐药的数据。
  • 将耐药MSSA分离株送至比利时葡萄球菌参考中心进行spa分型,并分析eta、etb毒力基因和mupA耐药基因。
  • 对2021年10月至2023年9月收集的MSSA分离株进行全基因组测序。

主要发现

  • 莫匹罗星耐药率从2013年的0.5-1.5%上升至2023年的1.7-5.6%。
  • 2018至2023年,91.4%(64/70)的莫匹罗星耐药分离株同时对夫西地酸耐药。
  • 截至2023年9月,两实验室儿童分离株共耐药率分别为8.9%(15/168)和10.1%(11/109)。
  • 33株测序分离株中29株为序列型121,呈克隆性,与2020年比利时观察到的EEFIC亲缘较远。
  • 这些分离株携带mupA和fusB基因,分别赋予莫匹罗星和夫西地酸耐药,并携带eta和etb毒力基因。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundAntimicrobial resistance to mupirocin and fusidic acid, which are used for treatment of skin infections caused by Staphylococcus aureus, is of concern.AimTo investigate resistance to fusidic acid and mupirocin in meticillin-susceptible S. aureus (MSSA) from community-acquired skin and soft tissue infections (SSTIs) in Belgium.MethodsWe collected 2013-2023 data on fusidic acid and mupirocin resistance in SSTI-associated MSSA from two large Belgian laboratories. Resistant MSSA isolates sent to the Belgian Staphylococci Reference Centre were spa-typed and analysed for the presence of the eta and etb virulence genes and the mupA resistance gene. In addition, we whole genome sequenced MSSA isolates collected between October 2021 and September 2023.ResultsMupirocin resistance increased between 2013 and 2023 from 0.5-1.5% to 1.7-5.6%. Between 2018 and 2023, 91.4% (64/70) of mupirocin-resistant isolates were co-resistant to fusidic acid. By September 2023, between 8.9% (15/168) and 10.1% (11/109) of children isolates from the two laboratories were co-resistant. Of the 33 sequenced isolates, 29 were sequence type 121, clonal and more distantly related to the European epidemic fusidic acid-resistant impetigo clone (EEFIC) observed in Belgium in 2020. These isolates carried the mupA and fusB genes conferring resistance to mupirocin and fusidic acid, respectively, and the eta and etb virulence genes.ConclusionWe highlight the spread of a mupirocin-resistant EEFIC in children, with a seasonal trend for the third quarter of the year. This is of concern because this variant is resistant to the two main topical antibiotics used to treat impetigo in Belgium.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Yin N, Michel C, Makki N, et al. Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of Staphylococcus aureus, Belgium, 2013 to 2023. Euro Surveill. 2024. PMID: 38726693. doi:10.2807/1560-7917.ES.2024.29.19.2300668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。